MXPA02005626A - Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente. - Google Patents

Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.

Info

Publication number
MXPA02005626A
MXPA02005626A MXPA02005626A MXPA02005626A MXPA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A
Authority
MX
Mexico
Prior art keywords
osteoporosis
ductus arteriosus
compositions
glomerular filtration
patent ductus
Prior art date
Application number
MXPA02005626A
Other languages
English (en)
Inventor
Krishna G Peri
Original Assignee
Pital Sainte Justine H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pital Sainte Justine H filed Critical Pital Sainte Justine H
Publication of MXPA02005626A publication Critical patent/MXPA02005626A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Water Treatment By Sorption (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Joints With Sleeves (AREA)

Abstract

La presente invencion se refiere a una composicion de una materia que comprende antagonistas novedosos del receptor de prostaglandina E2, y su uso en tratamientos para regular la filtracion de fluidos en el rinon, evitando la perdida mineral de los huesos en la osteoporosis y la enfermedad dental y adicionalmente, el cierre de los conductos arteriosos (DA) en infantes prematuros o animales fetales. Adicionalmente, las composiciones incluyen peptidos lineales, analogos peptidos, y peptidomimeticos.
MXPA02005626A 1999-12-06 2000-12-06 Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente. MXPA02005626A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45548399A 1999-12-06 1999-12-06
PCT/CA2000/001445 WO2001042281A1 (en) 1999-12-06 2000-12-06 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

Publications (1)

Publication Number Publication Date
MXPA02005626A true MXPA02005626A (es) 2004-09-10

Family

ID=23808998

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005626A MXPA02005626A (es) 1999-12-06 2000-12-06 Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.

Country Status (12)

Country Link
US (1) US7442763B2 (es)
EP (1) EP1244693B1 (es)
JP (1) JP2003516417A (es)
AT (1) ATE298346T1 (es)
AU (1) AU784630B2 (es)
CA (1) CA2396739A1 (es)
DE (1) DE60020997T2 (es)
ES (1) ES2246915T3 (es)
MX (1) MXPA02005626A (es)
NZ (1) NZ520762A (es)
WO (1) WO2001042281A1 (es)
ZA (1) ZA200205795B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
WO2001042281A1 (en) 1999-12-06 2001-06-14 Hôpital Sainte-Justine Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis
EP1467738A1 (en) * 2001-10-08 2004-10-20 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
ATE371454T1 (de) * 2001-10-31 2007-09-15 Medical Res Council Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
AU2003233297A1 (en) * 2002-05-23 2003-12-12 Theratechnologies Inc Antagonistic peptides of prostaglandin e2 receptor subtype ep4
EP1878741A3 (en) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
US7414029B2 (en) 2002-05-23 2008-08-19 Theratechnologies, Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
WO2004073589A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
EP2846793A1 (en) 2012-05-09 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
AU4855393A (en) * 1992-09-10 1994-03-29 New York University Polypeptides of g-coupled receptor proteins, and compositions and methods thereof
KR960700739A (ko) * 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
US5869281A (en) 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
WO1995011987A1 (en) * 1993-10-29 1995-05-04 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
CA2188432C (en) * 1994-04-22 2011-02-01 Yutaka Kawakami Melanoma antigens
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
WO1996006856A1 (en) * 1994-08-31 1996-03-07 Robert Webber Dopamine receptor peptides and anti-peptide antibodies
ATE300308T1 (de) * 1994-12-12 2005-08-15 Omeros Corp Bespüllungslösung und deren verwendung zur perioperativen hemmung von schmerzen, entzündungen und spasmen an einer wunde
NZ334998A (en) 1995-01-25 2000-11-24 Cor Therapeutics Inc Use of an agonist or antagonist for inhibiting the expression of a C140 receptor
US5877155A (en) * 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
US6117839A (en) * 1995-06-07 2000-09-12 Gensci Regeneration Sciences, Inc. Bone stimulating factor
AU2658897A (en) * 1996-03-21 1997-10-10 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
CA2265476A1 (en) * 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5955575A (en) * 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
AUPP320998A0 (en) * 1998-04-27 1998-05-21 Walter And Eliza Hall Institute Of Medical Research, The Tyrosine phosphatase IA-2 T-cell epitopes
US6984719B1 (en) * 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
WO2001042281A1 (en) 1999-12-06 2001-06-14 Hôpital Sainte-Justine Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

Also Published As

Publication number Publication date
DE60020997D1 (de) 2005-07-28
WO2001042281A1 (en) 2001-06-14
US20030017988A1 (en) 2003-01-23
JP2003516417A (ja) 2003-05-13
NZ520762A (en) 2005-02-25
AU2134001A (en) 2001-06-18
CA2396739A1 (en) 2001-06-14
EP1244693A1 (en) 2002-10-02
ATE298346T1 (de) 2005-07-15
EP1244693B1 (en) 2005-06-22
ES2246915T3 (es) 2006-03-01
ZA200205795B (en) 2007-01-31
AU784630B2 (en) 2006-05-18
US7442763B2 (en) 2008-10-28
DE60020997T2 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
MXPA02005626A (es) Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.
KR101956579B1 (ko) 상아질 지각과민증 완화를 위한 치약 조성물
BG107697A (en) Ep4 receptor selective agonists in the treatment of osteoporosis
PT861261E (pt) Sequências nucleotídicas e proteicas de genes delta de vertebrado e métodos nelas baseados
YU53502A (sh) Blokada aksonalnog rasta posredstvom nogo receptora
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
TR200301841T4 (tr) Osteoporoz tedavisinde EP4 reseptör seçici.
DE60038922D1 (de) Zusammensetzungen für den wiederaufbau von knochengewebe
AP2000001905A0 (en) Peptide compositions and formulations and use of same.
DK0664133T3 (da) "Ostim Apatit"-præparat til stimulering af vækst i knoglevæv
IL146009A0 (en) Stereoselective antifibrillogenic peptides and peptidomimetics thereof
EP0950417A3 (en) Treatment of skeletal disorders
TNSN98104A1 (fr) Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant.
PL329526A1 (en) Casein peptide containing tooth-cleaning composition of long shelf-life
HK1041449B (zh) 可在體內減少α2-抗纖溶酶的化合物在製備用於治療局部缺血性中風的組合物中的用途
BR112019018871A2 (pt) complexos para tratar sensibilidade
MX2007000120A (es) Composicion herbacea.
HK1041633A1 (en) Composition and use of rar antagonists for promoting chondrogenesis
DE02748548T1 (de) Calcium-l-threonat zur prävention oder behandlung von knochenfrakturen
JP2008074773A (ja) 口腔用組成物
IL143956A (en) Chimeric polypeptide having the antigenic determinants of four proteins of l. infantum, polynucleotides encoding same, methods of production and use thereof in therapeutic compositions
ATE357255T1 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
ATE429826T1 (de) Zusammensetzung zur prävention und/oder behandlung von verändertem knochenmetabolismus
EP1191099A4 (en) POLYPEPTIDES AND THEIR DNA
Iizuka et al. Chemical alteration by tooth bleaching of human salivary proteins that infiltrated subsurface enamel lesions—Experimental study with bovine lesion model systems—